A rationally designed agonist antibody fragment that functionally mimics thrombopoietin

被引:40
作者
Frederickson, Shana
Renshaw, Mark W.
Lin, Bing
Smith, Lynette M.
Calveley, Peter
Springhorn, Jeremy P.
Johnson, Krista
Wang, Yi
Su, Xiao
Shen, Yamin
Bowdish, Katherine S.
机构
[1] Alex Antibody Technol Inc, San Diego, CA 92121 USA
[2] Alex Pharmaceut Inc, Cheshire, CT 06410 USA
关键词
cMpl receptor;
D O I
10.1073/pnas.0602658103
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
By using rational design, antibody fragments (Fabs) that mimic thrombopoietin (TPO) were created. A peptide with cMpl receptor-binding capability was grafted into different complementarity-determining regions of a fully human Fab scaffold. Functional presentation of the peptide was optimized by using phage display and cell-based panning. Select antibodies and fragments containing two grafted peptides were assayed for their ability to stimulate the cMpl receptor in vitro. Several candidates demonstrated agonist activity in an in vitro cMpl receptor signaling reporter assay, including Fab59, which was estimated to be equipotent to TPO. Fab59 additionally was able to effectively stimulate platelet production in normal mice. These rationally designed mimetic Fabs may provide a therapeutic intervention for thrombocytopenia while avoiding the potential generation of neutralizing antibodies to endogenous TPO. Furthermore, this study demonstrates a method by which short-lived linear peptides with binding activity may be converted to more stable and potent agonists capable of activating cell surface receptors.
引用
收藏
页码:14307 / 14312
页数:6
相关论文
共 29 条
  • [11] Discovery and characterization of a selective, nonpeptidyl thrombopoietin receptor agonist
    Erickson-Miller, CL
    DeLorme, E
    Tian, SS
    Hopson, CB
    Stark, K
    Giampa, L
    Valoret, EI
    Duffy, KJ
    Luengo, JL
    Rosen, J
    Miller, SG
    Dillon, SB
    Lamb, P
    [J]. EXPERIMENTAL HEMATOLOGY, 2005, 33 (01) : 85 - 93
  • [12] Recent developments and emerging therapies for type 2 diabetes mellitus.
    Evans A.J.
    Krentz A.J.
    [J]. Drugs in R & D, 1999, 2 (2) : 75 - 94
  • [13] Structure of the receptor-binding domain of human thrombopoietin determined by complexation with a neutralizing antibody fragment
    Feese, MD
    Tamada, T
    Kato, Y
    Maeda, Y
    Hirose, M
    Matsukura, Y
    Shigematsu, H
    Muto, T
    Matsumoto, A
    Watarai, H
    Ogami, K
    Tahara, T
    Kato, T
    Miyazaki, H
    Kuroki, R
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2004, 101 (07) : 1816 - 1821
  • [14] Harker LA, 2000, BLOOD, V95, P2514
  • [15] Kabat EA, 1991, Sequences of Proteins of Immunological Interest
  • [16] Kimura T, 1997, J BIOCHEM-TOKYO, V122, P1046
  • [17] Effective ex vivo generation of megakaryocytic cells from mobilized peripheral blood CD34+ cells with stem cell factor and promegapoietin
    Kratz-Albers, K
    Scheding, S
    Möhle, R
    Bühring, HJ
    Baum, CM
    Mc Kearn, JP
    Büchner, T
    Kanz, L
    Brugger, W
    [J]. EXPERIMENTAL HEMATOLOGY, 2000, 28 (03) : 335 - 346
  • [18] Recombinant human thrombopoietin: basic biology and evaluation of clinical studies
    Kuter, DJ
    Begley, CG
    [J]. BLOOD, 2002, 100 (10) : 3457 - 3469
  • [19] Whatever happened to thrombopoietin?
    Kuter, DJ
    [J]. TRANSFUSION, 2002, 42 (03) : 279 - 283
  • [20] Thrombocytopenia caused by the development of antibodies to thrombopoietin
    Li, JZ
    Yang, C
    Xia, YP
    Bertino, A
    Glaspy, J
    Roberts, M
    Kuter, DJ
    [J]. BLOOD, 2001, 98 (12) : 3241 - 3248